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http:WHAT THIS PAPER ADDS
GPS can monitor community walking in PAD patients with claudication. Despite the apparent variability of GPS
derived parameters observed within a single stroll, the greatest distance walked between stops and the mean
walking speed are reliable parameters in test-retest recordings. GPS appears to be a new easy to use and low
cost way of evaluating walking ability in PAD patients. It could be useful to follow the walking ability of PAD
patients without laboratory referral. It could be of speciﬁc interest in private practice, in epidemiological studies,
or for patients coming from isolated geographic areas.Objective: In patients with peripheral artery disease (PAD), the different distances between stops and the stop
durations recorded with Global Positioning System (GPS) during a 1 hour stroll in the community are highly
variable. Nevertheless, the reliability of the greatest community walk distance (greatest distance), the average of
walking speeds (average speed) and the durations of stops (average stop durations) have not been studied.
Design: Seventeen PAD patients performed two series of evaluations (T1 and T2) within a 1 month period.
Methods: Each series included: a 1 hour stroll in the community with the calculation of the walking impairment
questionnaire (WIQ) scores, the measurement of maximal walking distance on a treadmill (MWD on treadmill)
and a 1 hour stroll in the community with GPS. The Garmin GPS-60 (Garmin Ltd, Olathe, Kan) receiver was used
for all patients. Test-retest reliability of MWD on treadmill, WIQ, and GPS parameters were assessed with
intraclass coefﬁcient of correlation (ICC).
Results: ICCs are almost perfect between T1 and T2 for greatest distance (ICC ¼ 0.911), average speed
(ICC ¼ 0.905), and MWD on treadmill (ICC ¼ 0.992), and substantial for the average WIQ (ICC ¼ 0.794).
Correlation of average stop durations was considered substantial (ICC ¼ 0.691).
Conclusions: Despite the previously reported “within stroll” variability of walking bouts for distances, speeds, and
stop durations, GPS derived greatest distance and average speed are reliable in PAD patients in test-retest
experiments. The GPS appears to be a new tool to assess walking limitation and allows objective clinical
investigation.
 2015 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Lower extremity peripheral artery disease (PAD) is a chronic
condition, for which the common initial symptom is char-
acterised by intermittent claudication. Claudication is
deﬁned as a pain or discomfort that limits walking ability,
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//dx.doi.org/10.1016/j.ejvs.2015.07.009within 10 minutes of stopping, then allowing further
walking.1e4 PAD is associated with a decrease in maximal
walking distance (MWD: the absolute maximum distance
walked before limb discomfort or pain forces the patient to
stop) and a decrease in walking speed. Reduced perfor-
mance is related to an increased risk of mortality.5 There are
various tools available to evaluate the characteristics asso-
ciated with walking limitation in patients with PAD. Among
available tools are questionnaires such as the walking
impairment questionnaire (WIQ)6e8 and treadmill tests.3,9
Each of these tools may evaluate the walking limitation,
but do not provide objective evaluation of walking in the
community (CW) such as the walking speed or the duration
624 M. Gernigon et al.of stops between walking bouts. Global Positioning System
(GPS) has been proposed as an original tool to measure
walking ability in PAD in the community.10e12 GPS can be
used to simultaneously evaluate distance, speed, and the
duration of stops, as well as record various walking bouts in
the same patient, provided that the recorded walking
period is long enough (45e60 min) to allow multiple
walking bouts within a single stroll. Further, with GPS, no
calibration (e.g. pedometers) or integration (e.g. acceler-
ometers) is needed to retrieve distance, speed, or time.
Previously, it was shown that during a GPS recorded pre-
scribed 1 hour stroll in the community, the various walking
speeds between stops (WSCW) for the different walking
bouts were relatively homogeneous, whereas large vari-
ability was found in stop durations between walking bouts
(DSCW).
13 Further, in routine clinical practice patients are
expected to have “a” MWD, used as an indicator. However,
previously a large variability was observed in the different
measured distances between two symptom limited stops
(MDCW) during a 1 hour stroll.
13 Despite this “within stroll”
variability of MDCW, the greatest of these various observed
MDCW values (greatest distance), correlates with the self
reported MWD11 and with the maximum distance per-
formed on treadmill (MWD on treadmill).10
An essential step for the potential use of GPS in PAD
patients is to determine the reliability of GPS derived pa-
rameters of walking ability. Ultimately, GPS appears to be a
new tool to assess the walking limitation and could become
another useful way to objectively assess walking of PAD
patients. The present study focused on the greatest dis-
tance, the average of walking speeds (average speed), and
the average of stop durations (average stop durations). The
aim of the present study was to estimate the test-retest
reliability of these GPS-derived parameters in PAD pa-
tients under community walking conditions. It was
hypothesised that, despite the large variability observed for
MDCW and DSCW within a 1 hour stroll, the greatest dis-
tance, the average speed and the average stop durations
would be reliable parameters in test-retest recordings.
MATERIALS AND METHODS
Patients
A prospective study was conducted to include 20 patients
with intermittent claudication. Because only one GPS was
available for the study and issues appeared with its sam-
pling rate, it took time to identify the issues, contact the
company, and replace the GPS, thus the inclusion period
was from October 2007 to March 2010. Inclusion criteria
included: age > 18 years old; stage II vascular type inter-
mittent claudication (Leriche and Fontaine classiﬁcation)
deﬁned as a fatigue, discomfort or pain occurring in the calf,
thigh, or buttock during exercise that resolved within 10
minutes of rest; an ankle brachial systolic pressures index
(ABI) < 0.90,14 or an ABI < 0.95 with an exercise trans-
cutaneous oxygen pressure (tcpO2) decrease from rest of
oxygen pressure (DROP) index < 15 mmHg15,16; ability to
attend the second series of evaluations; clinical stability ofthe severity of PAD in the 3 months preceding inclusion.
Exclusions included patients with any ongoing symptomatic
disease that limited exercise other than PAD (e.g. lumbar
spine syndrome, limiting exertional dyspnoea, or symp-
tomatic arthritis), and patients at risk from exercise tests
(myocardial infarction in the last 6 months, uncontrolled
angina pectoris, sustained cardiac arrhythmias, abdominal
aortic aneurysm > 40 mm). Moreover, both resting ABI3,4
and exercise DROP index15,16 were used to make the diag-
nosis of vascular claudication in isolated proximal claudi-
cation where ABI can remain within normal limits.17e19
The procedures used in this study were approved by the
CPP-Ouest II ethics committee and performed according to
the international ethics standards and the Declaration of
Helsinki. The study was promoted and monitored by the
University Hospital of Angers (France) and was registered in
the American National Institutes of Health database under
reference n NCT00485147 (www.ClinicalTrials.gov). All pa-
tients provided written informed consent to participate in
the study. After enrolment, two series of evaluations were
scheduled on two different days. Test 1 (T1) and test 2 (T2)
included laboratory and outdoor (GPS) evaluations of
walking ability. T2 was scheduled, at least 1 day and within 1
month of T1. Exclusion criteria included any change in the
medical treatment, any kind of surgical revascularisation
between T1 and T2, and missing GPS data in T1 or T2.
Laboratory investigations
After enrolment, height (cm), body mass (kg), ABI, comorbid
conditions, claudication history, cardiovascular risk factors,
medical or surgical history, and ongoing medications were
obtained from medical ﬁles as well as medical history and
physical examination. At both T1 and T2, laboratory evalu-
ations ﬁrst included the completion of the WIQ6 and then
the measurement of MWD on treadmill (3.2 km/h; 10%
grade; maximised to 20 minutes).15,18 The patients were
blinded to the results of each evaluation. As with T1, the
laboratory evaluations for T2 were performed on the same
day as the second GPS 1 hour stroll.
GPS investigations
The outdoor stroll was always performed on the same day
just after the laboratory investigations. The Garmin GPS-60
(Garmin Ltd, Olathe, Kan) was used on all patients. For
technical reasons, from patient 5, another type of GPS was
used simultaneously. Data for this second device are re-
ported as additional “online only” data. GPS were worn in a
backpack and the antenna was positioned on the right
shoulder. GPS devices were both started and stopped in the
laboratory before and after the stroll. Following a standard
procedure,13 patients were asked to perform a 1 hour stroll
(including stop durations) alone. The stroll was organised in
a pre-deﬁned public park near the hospital. This park is free
from cars or any kind of motorised vehicles, is relatively free
of compact trees, and contains a large variety of ﬂat
pedestrian paths. As previously published,10 patients were
asked to walk at their usual pace and only stop at maximal
Table 1. Patient characteristics.
Clinical characteristics n ¼ 17
Age, years 64  7
Weight, kg 79  15
Height, cm 166  7
Body mass index, kg/m2 28.5  4.2
Male sex, no. (%) 15 (88%)
Disease history, years 3.5 [1.4;8.5]
Ankle brachial index 0.75 [0.67;0.82]
TcPO2 DROP min, mmHg 32 [45;28]
Comorbidities, (history of), no. (%)
Smoker (current or former) 16 (94%)
Coronary disease 4 (24%)
Sleep apnoea 1 (6%)
Hypercholesterolaemia 8 (47%)
Diabetes 5 (29%)
History of vascular surgery (lower limbs) 5 (29%)
Current medications, no. (%)
Fibrates or statins 13 (76%)
Anti-diabetic 5 (29%)
Anti-hypertensive 12 (71%)
Beta blocker 8 (47%)
Antiplatelet 17 (100%)
Results are presented as mean  SD, median [25th;75th], or
number of observation (%).
Test-retest Reliability of GPS 625pain. The T2 stroll was performed in the same park, but not
necessarily using the same pedestrian paths.
Recorded data were downloaded to a personal computer
and analysed according to a previously published proce-
dure.10,13,20 For each recording, the methodology was used
as previously described, and all MDCW, WSCW, and DSCW
were calculated.10,13,20 From these parameters, the greatest
distance, average speed, and average stop durations were
extracted. The last MDCW and corresponding WSCW were
not used to calculate the greatest distance and average
speed except if the last MDCW was higher than any previ-
ously measured MDCW.
13
Weather conditions
Wind velocity, rain, and temperature at the time of each
recording were obtained from the local weather station.
Statistical analysis
The minimum number of patients needed to obtain a sta-
tistical power of 90% (p < .05) for a conﬁdent interval of
95% was 17. According to normal distribution, data are
expressed as mean  SD or as median with (25th to 75th
percentiles), where appropriate. For each laboratory and
community evaluation, the Bland-Altman plots21 and the
intraclass correlation coefﬁcient (ICC) with 95% conﬁdence
interval were performed to evaluate the test-retest reli-
ability. ICC values were ranked as poor (0.00e0.20), fair
(0.21e0.40), moderate (0.41e0.60), substantial (0.61e
0.80), or almost perfect (0.81e1.00).22 The student paired t
test (or Wilcoxon as appropriate) were performed to
compare T1 and T2 results. Statistical analyses were per-
formed with SPSS (V17.0.0 SPSS Inc., 2008). For all statistical
tests, a two tailed probability level of p < .05 was used to
indicate statistical signiﬁcance.
RESULTS
Three of the included patients had to be excluded (highly
noise non-interpretable signal or patient refusal to perform
the second series of laboratory evaluations). Characteristics
of the 17 patients are reported in Tables 1 and 2. Note that
data are missing for some questionnaires because of difﬁ-
culties and non-completion by the patients (Table 2).
Fig. 1 shows a typical example of the recordings observed
for the same patient during the two GPS strolls. There were
no signiﬁcant differences between the walks for tempera-
ture (p ¼ .65), wind (p ¼ .82) or rain (p ¼ .32). As shown in
Fig. 1, the footpaths used were different. Fig. 1 also clearly
illustrates the wide variability of MDCW observed for each
walking bout within each stroll, ranging from a minimum
MDCW of 90 m to a greatest distance of 487 m at T1 and
from a minimum MDCW of 228 m to a greatest distance of
550 m at T2. Also of interest is the fact that the speed (that
can be visually estimated from the slope of each walking
bout) is relatively stable between the different bouts and
between T1 and T2.
The median delay between T1 and T2 was 7 [6; 14] days.
Fig. 2 is the representation of reliability according to theBland-Altman analysis, and Tables 3 and 4 present the re-
sults of reliability analysis for both laboratory and GPS
evaluations. As shown in Table 3, laboratory measurements
showed almost perfect reliability for the MWD on treadmill.
From questionnaire results, WIQavg score, WIQ distance, and
WIQ speed sub-scores are substantial (i.e. 0.61 < ICC<0.80),
compared with the WIQ stairs climbing sub-score which is
almost perfect (0.81 < ICC). For GPS, an almost perfect
reliability was found for studied parameters between T1 and
T2 except for the average stop durations which is substantial
(Table 4 and Fig. 2). The correlation for GPS parameters
between T1 and T2 is high except for the duration of stops.
DISCUSSION
A community based approach is necessary to provide access
to healthcare for patients who cannot get to a hospital and
to contain health insurance costs. Despite the variability of
the different within stroll MDCW, the reliability of greatest
distance and average speed is good. Contrary to the study
hypothesis, average stop durations was not as reliable as
the other two parameters.
Multiple studies have addressed the question of MWD on
treadmill reliability (see the meta-regression analysis by
Nicolaï et al. for an exhaustive listing of these studies).23
The interpretation of reliability depends on the statistical
parameter used.24 For constant load protocols at 3.2 km/h
with a 10% (or 12%) gradient, available studies reported
ICCs ranging from 0.72 to 0.93.23 However, even if treadmill
evaluations are considered to be the gold standard method
for measuring walking impairment in PAD, they are time
consuming, expensive, and not readily accessible to all
physicians. Furthermore, one limitation is that the treadmill
does not satisfactorily reproduce the spontaneous
Table 2. Patient characteristics for each walking parameter.
N T1 T2
WIQa distance subscore (%) 16 36.0 [12.1; 62.7] 31.0 [17.1; 69.1]
WIQa speed subscore (%) 25.0 [14.1; 36.1] 28.3 [20.9; 41.0]
WIQa stairs subscore (%) 33.3 [16.6; 66.6] 44.8 [27.1; 66.6]
WIQa mean 36.8 [22.5; 46.6] 40.9 [21.2; 57.0]
Self reported MWD a b (m) 17 250 [100; 500] 500 [200; 700]
MWD on treadmillc (m) 17 109 [92; 138] 119 [82, 178]
Total distanceCW (m) 17 3139 [2267; 3700] 3125 [2185; 3643]
Total time durationCW (min) 61.23 [60.07; 70.87] 65.56 [59.00; 75.43]
Greatest distanced (m) 537 [351; 1620] 804 [324; 1532]
Average speede (km.h1) 3.42 [3.17; 3.92] 3.42 [2.95; 3.83]
Average stop durationsf (min) 1.30 [0.93; 2.58] 1.73 [1.25; 2.34]
Results are presented as median [25th:75th].
a WIQ: “walking impairment questionnaire”.
b Self reported MWD: “maximum walking distance self reported”.
c MWD on treadmill: “maximum walking distance performed on the treadmill”.
d Greatest distance: “greatest measured distance between two stops during community walking”.
e Average speed: “average walking speed during community walking”.
f Average stop durations: “average stop durations during community walking”.
626 M. Gernigon et al.community walk of PAD patients and is rarely used to
provide parameters such as spontaneous walking speed and
stop durations. This could be useful in vascular patients but
also in many other diseases (e.g. pulmonary or cardiac
disease, lumbar spine stenosis, etc.).
Among methodological approaches, a way of evaluating
walking speed is estimation through questionnaires. Sub-
stantial to almost perfect ICCs were found for WIQ sub-
scores. The ICC reported for WIQ sub-scores and scores
are in the range of those reported in other studies.26e28Figure 1. Example of the recordings observed during the two strolls (Tes
(black lines) were started at the parking lot, north of the park. The grap
stop.GPS appears to be an interesting tool for estimating
walking parameters in community conditions in diseased
patients and healthy subjects.10,13,20,29 Of interest the reli-
ability of test-retest greatest distance is in the high range of
those usually observed in test-retest recording of MWD on
treadmill in PAD patients.23,30e33 The almost perfect reli-
ability of greatest distance and average speed observed
here is an essential methodological prerequisite for long-
term follow up studies in PAD patients. GPS allows new
investigations of walking limitation parameters of PADt 1 and Test 2) in the same patient in the “Parc Balzac”. Both strolls
hs under each image represent cumulated distance between each
Figure 2. Test-retest reliability with Bland-Altman representation for the different GPS derived parameters between the two strolls.
Table 4. Walking parameter results for the patients that fully
completed both series of tests.
Test-retest Reliability of GPS 627patients such as speed and time recovery. These new pa-
rameters more precisely described the walking pattern and
may show the beneﬁt of treatment or surgery.
Potential advantages of GPS include the price of the test
and time saved. The GPS receiver can be used for multiple
patients. In the present study, the patient came back to
the laboratory to give the GPS back for analysis. More
recently the GPS is returned in a pre-stamped envelopeTable 3. Results at T1 and T2 of laboratory investigations.
N ICC [95% CI] (p) Wilcoxon
test
WIQdistance
a 16 0.616 [0.203; 0.845] (.003) 0.551
WIQspeed 0.749 [0.429; 0.904] (<.001) 0.551
WIQstairs 0.902 [0.749; 0.964] (<.001) 0.153
WIQmean 0.794 [0.515; 0.922] (<.001) 0.776
Self reported
MWDb (m)
17 0.473 [0.018; 0.769] (.021) 0.038
MWD on
treadmillc (m)
17 0.992 [0.978; 0.997] (<.001) 0.551
Results are presented as intraclass coefﬁcient of correlation (ICC),
and p for the Wilcoxon test.
a WIQ: “walking impairment questionnaire”.
b Self reported MWD: “maximum walking distance self reported”.
c MWD on treadmill: “maximum walking distance performed
during the treadmill test”.using regular surface mail system for less than 8 $.25 The
time required to manually analyse a GPS recording is 10e
20 minutes but will decrease with expertise and automa-
tion of the analyses.N ICC [95% CI] (p) Wilcoxon
test
Greatest
distancea (m)
17 0.911 [0.776; 0.966] (<.001) 0.306
Average
speedb (km.h1)
17 0.905 [0.762; 0.964] (<.001) 0.420
Average stop
durationsc (min)
15 0.691 [0.308; 0.883] (.001) 0.330
Number of stops 17 0.899 [0.750; 0.962] (<.001) 0.193
Total
distanceCW (m)
17 0.947 [0.863; 0.980] (<.001) 0.190
Results are presented as intraclass coefﬁcient of correlation (ICC),
the Pearson coefﬁcient with 95% conﬁdence interval [95% CI] and
the student t test.
a Greatest distance: “greatest measured distance between two
stops during community walking”.
b Average speed: “average walking speed during community
walking”.
c Average stop durations: “average stop durations during com-
munity walking”.
Table 5. List of abbreviations.
Abbreviations Meanings and deﬁnitions
DSCW Stop durations between walking bouts during
community walking
GPS Global Positioning System
ICC Intraclass coefﬁcient of correlation
MWD Maximal walking distance: the absolute
maximum distance walked before limb
discomfort or pain forces the patient to stop
MDCW Measured distance in community walking
between two symptom-limited stops.
One patient may have multiple measured
distances in a 1 hour recording
PAD Peripheral artery disease
WIQ Walking impairment questionnaire
WSCW Walking speed during community walking:
mean walking speed between two stops
during community walking
628 M. Gernigon et al.Study limitations
First, in addition to a non-formal standardisation between
T1 and T2 (i.e. within a month and the median period was 2
weeks), the route that the patients took and the environ-
mental conditions of temperature, wind speed/directions,
etc may have changed between T1 and T2 and could
potentially have an impact on reliability measures when
considering the community-based approach. Second, a
learning effect between T1 and T2 cannot be ruled out. This
could explain the slightly (although non-signiﬁcant)
improved ability at T2. Third, previous reports have sug-
gested a gender difference in the walking ability of PAD
patients.34 Unfortunately, the small sample size in this study
does not allow a gender speciﬁc analysis. Fourth, a 1 hour
stroll may appear an unusually long exercise for most PAD
patients leading to fatigue as a cause of walking impair-
ment. This is true but on the one hand, it has previously
been shown that cumulated time (and thus fatigue) was
assumed to be responsible for walking impairment in less
than 15% of patients during 1 hour strolls.13 On the other
hand, each patient was their own control and it is unlikely
that fatigue differed between T1 and T2. Nevertheless, the
authors agree that studies are needed to analyse the in-
ﬂuence of shortening the duration of the stroll on GPS
derived parameters. Fifth, all the GPS strolls were per-
formed in a single carefully selected park. Applicability of
the technique in non-ﬂat areas, dense environment, and
non-pre-deﬁned places remains to be studied. A recent
study provides answers to some of these issues.25 Coupling
GPS data with other activity monitors (accelerometers, gy-
roscopes, etc.) might facilitate the use of the technique in
obstructed environments and enable monitoring of both
indoor and outdoor activities. Sixth, there was no evidence
or proof that all stops were related to pain. This is a pitfall
of the technique as used here. Nevertheless, it is expected
that in future GPS devices may be able to record physio-
logical parameters (e.g. heart rate, near infrared spectros-
copy, temperature, etc.). Once again, the problem will be to
keep the price of these multi-parameter devices low andkeep the analysis of recorded data simple enough for
routine use. Last, if the aim is to record routine community
walks or to perform prolonged recordings for several hours
or days, the ethical issues related to the use of new
communication technologies and to the monitoring of daily
living should not be neglected.
CONCLUSION
The present study suggests that GPS technology offers new
perspectives in individual evaluation of walking ability, at
least in PAD. GPS derived greatest distance and average
speed are reliable measures of walking ability in PAD pa-
tients during test-retest 1 hour stroll recordings, despite the
previously reported “within stroll” variability of the
different recorded distances and stop durations. GPS allows
the investigation of walking limitation of PAD patients in
conditions as close as possible to a usual walk. A cohort
long-term follow up study is needed to analyse the effect of
treatments over greatest distance, average speed, or
walking pattern improvements in PAD patients with inter-
mittent claudication.
Please refer to Table 5 for abbreviations list.
CONFLICT OF INTEREST
None.
FUNDING
This study was supported by a grant from the University
Hospital of Angers with the support of the Société Française
de Médecine Vasculaire. The grant number was
CHU_PROMOTEUR_2005_04.
ACKNOWLEDGEMENT
The authors thank J-F Hamel for technical help.
APPENDIX A. SUPPLEMENTARY DATA
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.ejvs.2015.07.009
REFERENCES
1 Rose GA. The diagnosis of ischaemic heart pain and intermit-
tent claudication in ﬁeld surveys. Bull World Health Organ
1962;27:645e58.
2 Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA,
Halperin JL, et al. ACC/AHA 2005 Practice Guidelines for the
management of patients with peripheral arterial disease (lower
extremity, renal, mesenteric, and abdominal aortic): a collab-
orative report from the American Association for Vascular
Surgery/Society for Vascular Surgery, Society for Cardiovascular
Angiography and Interventions, Society for Vascular Medicine
and Biology, Society of Interventional Radiology, and the ACC/
AHA Task Force on Practice Guidelines (Writing Committee to
Develop Guidelines for the Management of Patients With Pe-
ripheral Arterial Disease): endorsed by the American Associa-
tion of Cardiovascular and Pulmonary Rehabilitation; National
Heart, Lung, and Blood Institute; Society for Vascular Nursing;
TransAtlantic Inter-Society Consensus; and Vascular Disease
Foundation. Circulation 2006;113:e463e654.
Test-retest Reliability of GPS 6293 Dormandy JA, Rutherford RB. Management of peripheral
arterial disease (PAD). TASC Working Group. TransAtlantic
Inter-Society Consensus (TASC). J Vasc Surg 2000;31:S1e296.
4 Creager MA, Belkin M, Bluth EI, Casey Jr DE, Chaturvedi S,
Dake MD, et al. 2012 ACCF/AHA/ACR/SCAI/SIR/STS/SVM/SVN/
SVS Key data elements and deﬁnitions for peripheral athero-
sclerotic vascular disease: a report of the American College of
Cardiology Foundation/American Heart Association Task Force
on Clinical Data Standards (Writing Committee to develop
Clinical Data Standards for peripheral atherosclerotic vascular
disease). J Am Coll Cardiol 2012;59:294e357.
5 McDermott MM, Tian L, Liu K, Guralnik JM, Ferrucci L, Tan J,
et al. Prognostic value of functional performance for mortality
in patients with peripheral artery disease. J Am Coll Cardiol
2008;51:1482e9.
6 Hiatt WR, Hirsch AT, Regensteiner JG, Brass EP. Clinical trials for
claudication. Assessment of exercise performance, functional
status, and clinical end points. Vascular Clinical Trialists. Cir-
culation 1995;92:614e21.
7 Mahe G, Ouedraogo N, Vasseur M, Faligant C, Saidi K,
Leftheriotis G, et al. Limitations of self reported estimates of
functional capacity using the walking impairment question-
naire. Eur J Vasc Endovasc Surg 2011;41:104e9.
8 Regensteiner JG, Ware Jr JE, McCarthy WJ, Zhang P, Forbes WP,
Heckman J, et al. Effect of cilostazol on treadmill walking,
community-based walking ability, and health related quality of
life in patients with intermittent claudication due to peripheral
arterial disease: meta-analysis of six randomized controlled
trials. J Am Geriatr Soc 2002;50:1939e46.
9 Duprez D, de Backer T, de Buyzere M, Clement DL. Estimation
of walking distance in intermittent claudication: need for
standardization. Eur Heart J 1999;20:641e4.
10 Le Faucheur A, Abraham P, Jaquinandi V, Bouye P, Saumet JL,
Noury-Desvaux B.Measurement ofwalking distance and speed in
patients with peripheral arterial disease: a novel method using a
global positioning system. Circulation 2008;117:897e904.
11 Tew G, Copeland R, Le Faucheur A, Gernigon M, Nawaz S,
Abraham P. Feasibility and validity of self reported walking
capacity in patients with intermittent claudication. J Vasc Surg
2013;57:1227e34.
12 Nordanstig J, Wann-Hansson C, Karlsson J, Lundstrom M,
Pettersson M, Morgan MB.Vascular quality of life questionnaire-
6 facilitates health related quality of life assessment in periph-
eral arterial disease. J Vasc Surg 2014;59:700e7.
13 Le Faucheur A, Noury-Desvaux B, Mahe G, Sauvaget T,
Saumet JL, Leftheriotis G, et al. Variability and short-term de-
terminants of walking capacity in patients with intermittent
claudication. J Vasc Surg 2010;51:886e92.
14 Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA,
Fowkes FG, et al. Inter-Society Consensus for the management
of peripheral arterial disease (TASC II). Eur J Vasc Endovasc
Surg 2007;33(Suppl 1):S1e75.
15 Abraham P, Picquet J, Vielle B, Sigaudo-Roussel D, Paisant-
Thouveny F, Enon B, et al. Transcutaneous oxygen pressure
measurements on the buttocks during exercise to detect
proximal arterial ischemia: comparison with arteriography.
Circulation 2003;107:1896e900.
16 Abraham P, Picquet J, Bouye P, L’Hoste P, Enon B, Vielle B, et al.
Transcutaneous oxygen pressure measurements (tcpO2) at
ankle during exercise in arterial claudication. Int Angiol
2005;24:80e8.
17 Ouedraogo N, Barbeau C, Legrand M, Marchand J,
Leftheriotis G, Abraham P. “Routine” arterial echo-doppler isnot sufﬁcient to exclude an arterial origin of exercise-induced
proximal lower limb pain. Int J Cardiol 2013;167:1053e4.
18 Jaquinandi V, Picquet J, Bouye P, Saumet JL, Leftheriotis G,
Abraham P. High prevalence of proximal claudication among
patients with patent aortobifemoral bypasses. J Vasc Surg
2007;45:312e8.
19 Picquet J, Jacquinandi V, Saumet JL, Leftheriotis G, Enon B,
Abraham P. Systematic diagnostic approach to proximal-
without-distal claudication in a vascular population. Eur J Int
Med 2005;16:575e9.
20 Le Faucheur A, Abraham P, Jaquinandi V, Bouye P, Saumet JL,
Noury-Desvaux B. Study of human outdoor walking with a low-
cost GPS and simple spreadsheet analysis. Med Sci Sports Exerc
2007;39:1570e8.
21 Bland JM, Altman DG. Statistical methods for assessing
agreement between two methods of clinical measurement.
Lancet 1986;8:307e10.
22 Landis JR, Koch GG. The measurement of observer agreement
for categorical data. Biometrics 1977;33:159e74.
23 Nicolai SP, Viechtbauer W, Kruidenier LM, Candel MJ,
Prins MH, Teijink JA. Reliability of treadmill testing in pe-
ripheral arterial disease: a meta-regression analysis. J Vasc
Surg 2009;50:322e9.
24 Gernigon M, Le Faucheur A, Laneelle D, Noury-Desvaux B,
Mahe G, Abraham P. Reliability of GPS measurements to assess
walking limitation in patients with intermittent claudication.
Fundam Clin Pharmacol 2014;28:10.
25 Gernigon M, Le Faucheur A, Noury-Desvaux B, Mahe G,
Abraham P. Applicability of global positioning system for the
assessment of walking ability in patients with arterial claudi-
cation. J Vasc Surg 2014;60:973e81.
26 Coyne KS, Margolis MK, Gilchrist KA, Grandy SP, Hiatt WR,
Ratchford A, et al. Evaluating effects of method of adminis-
tration on Walking Impairment Questionnaire. J Vasc Surg
2003;38:296e304.
27 Long J, Modrall JG, Parker BJ, Swann A, Welborn 3rd MB,
Anthony T. Correlation between ankle brachial index, symp-
toms, and health related quality of life in patients with pe-
ripheral vascular disease. J Vasc Surg 2004;39:723e7.
28 Verspaget M, Nicolai SP, Kruidenier LM, Welten RJ, Prins MH,
Teijink JA. Validation of the Dutch version of the Walking Impair-
ment Questionnaire. Eur J Vasc Endovasc Surg 2009;37:56e61.
29 Perrin O, Terrier P, Ladetto Q, Merminod B, Schutz Y.
Improvement of walking speed prediction by accelerometry
and altimetry, validated by satellite positioning. Med Biol Eng
Comput 2000;38:164e8.
30 Zwierska I, Nawaz S, Walker RD, Wood RF, Pockley AG,
Saxton JM. Treadmill versus shuttle walk tests of walking ability
in intermittent claudication. Med Sci Sports Exerc 2004;36:
1835e40.
31 Kirby RL, Marlow RW. Reliability of walking endurance with an
incremental treadmill test. Angiology 1987;38:524e9.
32 Montgomery PS, Gardner AW. The clinical utility of a six-minute
walk test in peripheral arterial occlusive disease patients. J Am
Geriatr Soc 1998;46:706e11.
33 Falkensammer J, Gasteiger S, Polaschek B, Gruber I, Frech A,
Fraedrich G, et al. Reliability of constant-load treadmill testing
in patients with intermittent claudication. Int Angiol 2012;31:
150e5.
34 McDermott MM, Greenland P, Liu K, Criqui MH, Guralnik JM,
Celic L, et al. Sex differences in peripheral arterial disease: leg
symptoms and physical functioning. J Am Geriatr Soc 2003;51:
222e8.
